The goal of the Biomarkers Consortium Bone Quality Project is to advance the qualification of biomarkers for drug development and patient management in osteoporosis.
Over the last 20 years, great progress has been made in the diagnosis and treatment of the disease. Many large randomized trials have shown that osteoporosis treatments can reduce fracture risk in both men and women and may be contributing to the decrease seen in hip fracture incidence over the last decade. Despite these advances, there are important limitations to the current approaches to diagnosis and treatment of osteoporosis. Furthermore, recent concerns about osteonecrosis of the jaw and atypical femur fractures have prompted regulatory agencies to review the safety of potent antiresorptive drugs for osteoporosis. There is, thus, a tremendous, immediate need for development of new drugs and improvement of existing therapies, which the Bone Quality Project seeks to address. The project aims to evaluate osteoporosis biomarkers - including biochemical and imaging measures of the disease - and qualify them for use in drug development.